Stock Scorecard



Stock Summary for Aldeyra Therapeutics Inc (ALDX) - $2.22 as of 5/12/2025 7:45:42 PM EST

Total Score

10 out of 30

Safety Score

28 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ALDX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ALDX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ALDX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ALDX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ALDX (28 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ALDX

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - Aldeyra Therapeutics ( NASDAQ:ALDX ) , Robinhood Markets ( NASDAQ:HOOD ) 5/8/2025 1:00:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX - Aldeyra Therapeutics ( NASDAQ:ALDX ) 5/5/2025 6:12:00 PM
ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, Inc.? Contact BFA Law about Securities Investigation ( NASDAQ:ALDX ) - Aldeyra Therapeutics ( NASDAQ:ALDX ) 5/5/2025 11:53:00 AM
ALDX INQUIRY NOTICE: Aldeyra Therapeutics ( NASDAQ:ALDX ) Investors may have been affected by Securities Violations -- Contact BFA Law - Aldeyra Therapeutics ( NASDAQ:ALDX ) 5/3/2025 11:18:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX - Aldeyra Therapeutics ( NASDAQ:ALDX ) 4/29/2025 3:16:00 PM
ALDX ALERT: Aldeyra Therapeutics ( NASDAQ:ALDX ) Investors are Reminded of Pending Securities Investigation - Contact BFA Law - Aldeyra Therapeutics ( NASDAQ:ALDX ) 4/29/2025 12:41:00 PM
ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics ( NASDAQ:ALDX ) is being Investigated after 75% Stock Drop - Investors are Urged to Contact BFA Law - Aldeyra Therapeutics ( NASDAQ:ALDX ) 4/27/2025 12:20:00 PM
ALDX SHAREHOLDER ALERT: BFA Law Reminds Aldeyra Therapeutics, Inc. Investors of the Continuing Securities Investigation 4/26/2025 11:08:00 AM
ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) 75% Stock Drop Triggers Investigation - Contact BFA Law if You Lost Money - Aldeyra Therapeutics ( NASDAQ:ALDX ) 4/25/2025 11:36:00 AM
LEGAL NOTICE: Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) Investors are Notified of the Pending Securities Investigation - Contact BFA Law - Aldeyra Therapeutics ( NASDAQ:ALDX ) 4/23/2025 12:18:00 PM

Financial Details for ALDX

Company Overview

Ticker ALDX
Company Name Aldeyra Therapeutics Inc
Country USA
Description Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 2.22
Price 4 Years Ago 4.00
Last Day Price Updated 5/12/2025 7:45:42 PM EST
Last Day Volume 1,093,390
Average Daily Volume 2,915,255
52-Week High 2.82
52-Week Low 1.90
Last Price to 52 Week Low 16.84%

Valuation Measures

Trailing PE N/A
Industry PE 30.10
Sector PE 47.92
5-Year Average PE -4.22
Free Cash Flow Ratio 2.44
Industry Free Cash Flow Ratio 18.49
Sector Free Cash Flow Ratio 30.82
Current Ratio Most Recent Quarter 5.59
Total Cash Per Share 0.91
Book Value Per Share Most Recent Quarter 1.19
Price to Book Ratio 1.69
Industry Price to Book Ratio 35.42
Sector Price to Book Ratio 27.83
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 89.39
Sector Price to Sales Ratio Twelve Trailing Months 25.47
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 59,709,000
Market Capitalization 132,553,980
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -48.77%
Reported EPS 12 Trailing Months -0.94
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.94
Net Income Twelve Trailing Months -55,851,444
Net Income Past Year -55,851,444
Net Income Prior Year -37,542,510
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 54,527,092
Total Cash Past Year 54,527,092
Total Cash Prior Year 142,823,016
Net Cash Position Most Recent Quarter 39,527,092
Net Cash Position Past Year 39,527,092
Long Term Debt Past Year 15,000,000
Long Term Debt Prior Year 16,335,000
Total Debt Most Recent Quarter 15,000,000
Equity to Debt Ratio Past Year 0.83
Equity to Debt Ratio Most Recent Quarter 0.83
Total Stockholder Equity Past Year 71,004,871
Total Stockholder Equity Prior Year 119,795,030
Total Stockholder Equity Most Recent Quarter 71,004,871

Free Cash Flow

Free Cash Flow Twelve Trailing Months -43,208,751
Free Cash Flow Per Share Twelve Trailing Months -0.72
Free Cash Flow Past Year -43,208,747
Free Cash Flow Prior Year -30,326,130

Options

Put/Call Ratio 0.08
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.43
MACD Signal -0.52
20-Day Bollinger Lower Band 0.95
20-Day Bollinger Middle Band 4.61
20-Day Bollinger Upper Band 8.27
Beta 0.90
RSI 38.53
50-Day SMA 4.78
150-Day SMA 5.52
200-Day SMA 5.62

System

Modified 5/12/2025 5:01:59 PM EST